Evidence map›Paper›PMID 23332604›Full record

Trial reportGastrointestinal endoscopy2013

Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.

Patrick M Lynch, Jeffrey S Morris, William A Ross, Miguel A Rodriguez-Bigas, Juan Posadas, Rossa Khalaf, Diane M Weber, Valerie O Sepeda, Bernard Levin, Imad Shureiqi

Registry-linked trialAbstract readClinical Trial, Phase II
In one paragraph

Trial report in Gastrointestinal endoscopy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00503035 (Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00503035 phase2completednot on this map

Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2003 to 2021Enrolled51ConditionsFamilial Adenomatous PolyposisArmsCelecoxib, Colonoscopy Biopsy
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Assessing barriers to a rational chemoprevention trial design in young patients with familial adenomatous polyposis.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2017
    Article
  4. Review
  5. Article
  6. Chemoprevention of hereditary colon cancers: time for new strategies.Nature reviews. Gastroenterology & hepatology · 2016
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Patrick M LynchDepartment of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA. plynch@mdanderson.org
Jeffrey S Morris
William A Ross
Miguel A Rodriguez-Bigas
Juan Posadas
Rossa Khalaf
Diane M Weber
Valerie O Sepeda
Bernard Levin
Imad Shureiqi

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
5-LOX-1 and Clinical Chemoprevention of Colon TumorsR01CA106577 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHUREIQI, IMAD · 2005 to 2008
$1.3M
15-LOX-1 effects on colitis and colon cancerR01CA137213 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHUREIQI, IMAD · 2009 to 2012
$1.3M
NCI NIH HHS CA016672NCI NIH HHS CA137213NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA106577NCI NIH HHS R01 CA137213NCI NIH HHS R01S CA106577
6 · The paper itself

Abstract

backgroundAccurate measures of the total polyp burden in familial adenomatous polyposis (FAP) are lacking. Current assessment tools include polyp quantitation in limited-field photographs and qualitative total colorectal polyp burden by video.

objectiveTo develop global quantitative tools of the FAP colorectal adenoma burden.

designA single-arm, phase II trial. PATIENTS: Twenty-seven patients with FAP.

interventionTreatment with celecoxib for 6 months, with before-treatment and after-treatment videos posted to an intranet with an interactive site for scoring. MAIN OUTCOME MEASUREMENTS: Global adenoma counts and sizes (grouped into categories: <2 mm, 2-4 mm, and >4 mm) were scored from videos by using a novel Web-based tool. Baseline and end-of-study adenoma burden results were summarized by using 5 models. Correlations between pairs of reviewers were analyzed for each model.

resultsInterobserver agreement was high for all 5 measures of polyp burden. Measures that used both polyp count and polyp size had better interobserver agreement than measures based only on polyp count. The measure in which polyp counts were weighted according to diameter, calculated as (1) × (no. of polyps <2 mm) + (3) × (no. of polyps 2-4 mm) + (5) × (no. of polyps >4 mm) had the highest interobserver agreement (Pearson r = 0.978 for two gastroenterologists, 0.786 and 0.846 for the surgeon vs each gastroenterologist). Treatment reduced the polyp burden by these measurements in 70% to 89% of patients (P < .001). LIMITATIONS: Phase II study.

conclusionThis novel, Web-based polyp scoring method provides a convenient and reproducible way to quantify the global colorectal adenoma burden in FAP patients and a framework for developing a clinical staging system for FAP.

Indexed as

Computer Communication NetworksTumor BurdenAdenomaAdenomatous Polyposis ColiAdolescentAdultAntineoplastic AgentsCelecoxibColorectal NeoplasmsFemaleHumansMaleMathematical ConceptsMiddle AgedObserver VariationPyrazolesAntineoplastic AgentsCelecoxibPyrazolesSulfonamides

Identifiers

PMID23332604
PMCPMC3574220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.